Candel Therapeutics, Inc. announced the appointment of Nicoletta Loggia, PhD, RPh, to the Companys Board of Directors (Board) effective June 7, 2023. Dr. Loggia has more than 20 years of leadership experience delivering on all facets of technical operations within the biopharmaceutical industry. Her expertise spans the development and commercialization of biologics, small molecules, and cell and gene therapies.

She has served as the Chief Technical Officer for Orchard Therapeutics plc (Orchard) since September 2021, where she is responsible for CMC process and analytical development, manufacturing, supply chain, distribution, and global quality. Before Orchard, Dr. Loggia served as Global Head of Cell and Gene Therapies at Novartis AG (Novartis), where she led multidisciplinary international teams responsible for the end-to-end technical development, manufacturing and project management of several gene and cell therapies, including lentivirus, adeno-associated virus (AAV), stem and CAR-T cell processes, from concept to commercialization. She oversaw the integration of the CAR-T teams and AveXis AAV technical capabilities into Novartis technical research and development.

Dr. Loggia obtained her PhD in pharmaceutical technologies from the University of Pavia in Italy. She is also a registered pharmacist and member of the UK Royal and Italian Pharmaceutical societies.